A phase I study of tremelimumab, durvalumab, and hypofractionated radiotherapy for metastatic gynecologic cancers (040)
Lilie L. Lin(The University of Texas MD Anderson Cancer Center), Kevin Albuquerque(Southwestern Medical Center), Ann H. Klopp(The University of Texas MD Anderson Cancer Center), Jayanthi Lea(Southwestern Medical Center), Aradhana M. Venkatesan(National Institutes of Health), Penny Fang, Chika Nwachukwu(UC San Diego Health System), Pamela Boimel(Albert Einstein College of Medicine), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Kelly Rangel(The University of Texas MD Anderson Cancer Center), Diana L. Urbauer(The University of Texas MD Anderson Cancer Center)
Cited by 1
Related Papers
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Concise Review: Dissecting a Discrepancy in the Literature: Do Mesenchymal Stem Cells Support or Suppress Tumor Growth?
|Stem Cells|2010|571
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
|Nature Medicine|2023|508